菜单

CRO Services

Drug Development Expertise Empowering Research Services for Biologics

 

 

The complexity and heterogeneity of protein therapeutics present significant challenges in biologics discovery, as post-translational modifications (PTMs) and sequence variants can affect product quality, safety, and efficacy. Mass Spec (MS) has emerged as a powerful tool for structure and function analysis with unmatched precision and high-throughput (HTP) capabilities.

 

This webinar will showcase advanced MS methodologies, such as HTP Intact Mass, peptide mapping, and glycan analysis, for both qualitative physicochemical characterization and quantitative analysis for target validation and PK assessment. Real-world case studies will demonstrate how these approaches deliver comprehensive structure and function insights, driving more definitive biologics discovery and optimization.

 

You’ll discover how MS can:

 

  • Provide in-depth protein characterization to guide discovery, engineering, and optimization
  • Support robust in vitro and in vivo PK analysis to mitigate development risks
  • Address early-stage developability challenges with tailored workflows

 

 

Webinar Details

 

Date: Thursday, October 30, 2025

Time: 9:00 AM PT | 12:00 PM ET | 4:00 PM GMT

 

 

Speaker:

 

 

 

Lei Guo, Ph.D.

Senior Director, CRO Services

 

Dr. Lei Guo leads the Protein Analytical Chemistry group in WuXi Biologics CRO Services Department. Her team specializes in comprehensive analytical testing of monoclonal antibodies, bispecific antibodies, ADCs, and fusion proteins in drug discovery and optimization stages, employing Mass Spec for physicochemical and biophysical analyses. With over 14 years of experience in bioanalysis, Dr. Guo has held diverse roles at Pfizer, Sanofi, and MSD, contributing to target discovery, drug development, and CMC-stage analysis.

Enter your information to watch the recording

 

Have specific questions about LC-MS analysis?

Reach out to our experts!